BRIEF published on 10/26/2026 at 07:10, 11 days 4 hours ago TME Pharma Extends Debt Maturity to Enhance Financial Visibility Shareholder Value Debt Maturity Financial Stability Bond Financing NOX-A12 Licensing
PRESS RELEASE published on 10/26/2026 at 07:05, 11 days 4 hours ago TME Pharma extends financial visibility by lengthening debt maturity to June 2028
BRIEF published on 09/16/2026 at 08:05, 1 month 20 days ago TME Pharma NV's strategy and financial commitment Biotechnology Partnerships Financial Strategy TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 1 month 20 days ago TME PHARMA CEO MESSAGE TME Pharma CEO message emphasizes strategic approach, financial discipline, and long-term value creation for shareholders. Updates on NOX-A12, cost-reduction strategy, and future plans CEO Message Financial Discipline TME Pharma Strategic Approach NOX-A12
BRIEF published on 08/24/2026 at 08:10, 2 months 13 days ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
PRESS RELEASE published on 08/24/2026 at 08:05, 2 months 13 days ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
BRIEF published on 10/30/2025 at 21:05, 1 year ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 1 year ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 1 year 2 months ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 1 year 2 months ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
Published on 11/06/2026 at 05:15, 6 hours 8 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 00:53, 10 hours 30 minutes ago Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution
Published on 11/06/2026 at 00:45, 10 hours 38 minutes ago Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/06/2026 at 10:28, 55 minutes ago Tradegate BSX continues to expand its reach in the German retail investor market
Published on 11/06/2026 at 10:15, 1 hour 8 minutes ago Marco Fuchs Receives EY Entrepreneur Of The Year 2026 Award
Published on 11/06/2026 at 10:05, 1 hour 18 minutes ago Smart City Expo 2026 closes after showing the real impact of urban solutions
Published on 11/06/2026 at 09:58, 1 hour 25 minutes ago EQS-Adhoc: Uniper SE establishes dividend policy
Published on 11/06/2026 at 09:42, 1 hour 40 minutes ago Silver for the Thorium Pioneer: Emerald Horizon Takes Second Place at “Innovator of the Year” 2026
Published on 11/05/2026 at 18:21, 17 hours 1 minute ago Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:45, 17 hours 38 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 17 hours 54 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
